NICE has said Biogen's Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results from the EVOLVE-MS-1 study show ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

An agent biologically similar to the humanized monoclonal antibody natalizumab is as effective and safe as the original reference drug for relapsing-remitting multiple sclerosis (RRMS) — and has a ...